Suppr超能文献

伴有门静脉血栓形成的肝癌患者的特征:白蛋白与生存情况。

Characteristics of HCC Patients with Portal Vein Thrombosis: Albumin and Survival.

作者信息

Carr Brian, Donghia Rossella, Yilmaz Sezai

机构信息

Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya, Turkey.

National Institute of Gastroenterology, IRCCS "Saverio de Bellis", Bari, Italy.

出版信息

Oncology. 2024 Dec 9:1-10. doi: 10.1159/000542774.

Abstract

INTRODUCTION

Presence of macroscopic portal vein thrombosis (PVT) in patients with hepatocellular carcinoma (HCC) has been found to be a major poor prognosis characteristic.

AIMS

The aim of the study was to examine patients with PVT for their clinical characteristics and factors related to both PVT and survival.

METHODS

A large HCC database containing 1,094 patients with PVT and 2,513 patients without PVT was examined. Patients had routine baseline serum liver parameters and alpha-fetoprotein (AFP) levels measured, as well as radiological assessment of maximum tumor diameter (MTD), tumor number, presence of macroscopic PVT, plus survival.

RESULTS

The percent of patients with PVT increased with increase in both MTD and serum AFP levels and liver parameter levels were worse in patients with PVT than without it. A logistic regression model showed that the combination of MTD >5 cm plus AFP >100 IU/mL plus albumin <3.5 g/dL had an odds ratio of 10.988 for the presence of PVT. Normal serum albumin levels significantly reduced the hazard ratio for death in a Cox proportional hazard model and were associated with decreased liver failure.

CONCLUSION

Logistic regression showed the significance of MTD, AFP, and albumin in the presence of PVT, and the Cox model highlighted the importance of albumin levels in decreasing death.

摘要

引言

肝细胞癌(HCC)患者中存在肉眼可见的门静脉血栓形成(PVT)已被发现是一个主要的预后不良特征。

目的

本研究的目的是检查患有PVT的患者的临床特征以及与PVT和生存相关的因素。

方法

检查了一个大型HCC数据库,其中包含1094例患有PVT的患者和2513例未患有PVT的患者。对患者进行了常规基线血清肝脏参数和甲胎蛋白(AFP)水平的测量,以及对最大肿瘤直径(MTD)、肿瘤数量、肉眼可见PVT的存在情况以及生存情况的影像学评估。

结果

患有PVT的患者百分比随着MTD和血清AFP水平的升高而增加,并且患有PVT的患者的肝脏参数水平比未患PVT的患者更差。逻辑回归模型显示,MTD>5 cm加上AFP>100 IU/mL加上白蛋白<3.5 g/dL的组合对于存在PVT的比值比为10.988。在Cox比例风险模型中,正常血清白蛋白水平显著降低了死亡风险比,并且与肝衰竭的减少相关。

结论

逻辑回归显示了MTD、AFP和白蛋白在存在PVT时的重要性,并且Cox模型突出了白蛋白水平在降低死亡方面的重要性。

相似文献

2
Small hepatocellular carcinomas and thrombocytopenia.
Oncology. 2012;83(6):331-8. doi: 10.1159/000341533. Epub 2012 Sep 18.
4
Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma.
Oncology. 2012;83(6):339-45. doi: 10.1159/000342431. Epub 2012 Sep 18.
5
Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study.
J Cancer Res Clin Oncol. 1998;124(7):397-400. doi: 10.1007/s004320050189.
6
Macroscopic Portal Vein Thrombosis in HCC Patients.
Can J Gastroenterol Hepatol. 2018 Jun 13;2018:3120185. doi: 10.1155/2018/3120185. eCollection 2018.

本文引用的文献

6
I irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis.
Cancer Radiother. 2021 Jun;25(4):340-349. doi: 10.1016/j.canrad.2020.12.003. Epub 2021 Jan 14.
7
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.
Cancer Immunol Immunother. 2021 Jul;70(7):1929-1937. doi: 10.1007/s00262-020-02845-9. Epub 2021 Jan 6.
8
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.
Hepatol Res. 2020 Dec;50(12):1375-1385. doi: 10.1111/hepr.13567. Epub 2020 Sep 26.
9
Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma.
J Gastrointest Cancer. 2020 Dec;51(4):1141-1147. doi: 10.1007/s12029-020-00489-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验